Currently out of the existing stock ratings of Emmanuel Papadakis, 31 are a SELL (26.72%), 43 are a HOLD (37.07%), 42 are a BUY (36.21%).

Emmanuel Papadakis

Work Performance Price Targets & Ratings Chart

Analyst Emmanuel Papadakis, currently employed at DEUTSCHE BANK, carries an average stock price target met ratio of 52.94% that have a potential upside of 46.49% achieved within 312 days.

Emmanuel Papadakis’s has documented 217 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 15-Nov-2024.

Wall Street Analyst Emmanuel Papadakis

Analyst best performing recommendations are on ALVO (ALVOTECH).
The best stock recommendation documented was for MRNA (MODERNA) at 3/7/22. The price target of $155 was fulfilled within 9 days with a profit of $28.54 (22.57%) receiving and performance score of 25.08.

Average potential price target upside

of $42.8 (12.48%) on ARGX (ARGENX NV ADR).
of $39.05 (12.67%) on MRNA (MODERNA).
of $24.7 (8.99%) on BNTX (BIONTECH SE).

AZN AstraZeneca PLC ADR GLPG Galapagos NV ADR GRFS Grifols SA ADR GSK GlaxoSmithKline PLC ADR MRNA Moderna NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR ARGX argenx NV ADR GMAB Genmab AS MOR MorphoSys AG ADR ALVO Alvotech LBTSF Almirall RHHBY Roche Holding Ltd ADR BNTX BioNTech SE

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Michael Leuchten (UBS)